AU2020356626A1 - Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption - Google Patents

Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption Download PDF

Info

Publication number
AU2020356626A1
AU2020356626A1 AU2020356626A AU2020356626A AU2020356626A1 AU 2020356626 A1 AU2020356626 A1 AU 2020356626A1 AU 2020356626 A AU2020356626 A AU 2020356626A AU 2020356626 A AU2020356626 A AU 2020356626A AU 2020356626 A1 AU2020356626 A1 AU 2020356626A1
Authority
AU
Australia
Prior art keywords
biomarkers
composition
glycocalyx
kit
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020356626A
Other languages
English (en)
Inventor
Josefino B. Tunac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arterez Inc
Original Assignee
Arterez Inc
Arterez Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arterez Inc, Arterez Inc filed Critical Arterez Inc
Publication of AU2020356626A1 publication Critical patent/AU2020356626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020356626A 2019-09-27 2020-09-25 Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption Abandoned AU2020356626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907389P 2019-09-27 2019-09-27
US62/907,389 2019-09-27
PCT/US2020/052912 WO2021062298A1 (en) 2019-09-27 2020-09-25 Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Publications (1)

Publication Number Publication Date
AU2020356626A1 true AU2020356626A1 (en) 2022-04-14

Family

ID=75166872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020356626A Abandoned AU2020356626A1 (en) 2019-09-27 2020-09-25 Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Country Status (7)

Country Link
US (1) US20220390454A1 (https=)
EP (1) EP4034164A4 (https=)
JP (1) JP7689518B2 (https=)
AU (1) AU2020356626A1 (https=)
CA (1) CA3155843A1 (https=)
IL (1) IL291667A (https=)
WO (1) WO2021062298A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US12105099B2 (en) 2021-04-28 2024-10-01 Diotex Diagnostics, Llc Methods and devices for quantitatively estimating syndecan-1
CN115389773A (zh) * 2022-09-22 2022-11-25 无锡市第二人民医院 糖萼脱落标志物在诊断和防治初发的2型糖尿病肾病早期肾损伤的应用
WO2025049608A1 (en) * 2023-08-28 2025-03-06 Calroyhealth Sciences, Llc Compositions and methods to protect and enhance structural and functional integrity of the intestinal glycocalyx

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2437491T3 (es) * 2003-10-10 2014-01-10 Alchemia Oncology Pty Limited Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008080030A2 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Cardiovascular autoimmune disease panel and methods of using same
WO2011115783A1 (en) * 2010-03-15 2011-09-22 Oregon Health & Science University Methods for assessing the risk of cardiovascular disease
WO2012106152A1 (en) * 2011-02-03 2012-08-09 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
US9086412B2 (en) * 2012-12-31 2015-07-21 University Of Louisville Research Foundation, Inc. Extracellular vesicle-associated protein markers of cancer
EP2965088B1 (en) * 2013-03-04 2018-12-05 IQ Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
WO2016123163A2 (en) * 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) * 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2016176089A1 (en) * 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2017136652A1 (en) * 2016-02-04 2017-08-10 Tarveda Therapeutics, Inc. Stapled peptide conjugates and particles
JP7420557B2 (ja) * 2017-03-07 2024-01-23 オルト－クリニカル ダイアグノスティックス インコーポレイテッド 分析物を検出するための方法

Also Published As

Publication number Publication date
WO2021062298A1 (en) 2021-04-01
JP2022549373A (ja) 2022-11-24
IL291667A (en) 2022-05-01
EP4034164A1 (en) 2022-08-03
CA3155843A1 (en) 2021-04-01
JP7689518B2 (ja) 2025-06-06
EP4034164A4 (en) 2024-01-24
US20220390454A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP7689518B2 (ja) グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル
US11707475B2 (en) Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
JP6568917B2 (ja) 抗体及び防腐剤を含む安定した多用量組成物
TW201315482A (zh) ＩＬ－１β結合抗體之用途
JP6198277B2 (ja) 血液凝固促進に使用するための化合物
JP2011526485A (ja) 血栓障害および自己免疫障害の処置におけるｃｄ３１ペプチドの使用
ES2959277T3 (es) Composiciones y métodos para terapias antitrombóticas y hemostáticas
US20220288110A1 (en) Drug treatment and biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
JPWO2021062298A5 (https=)
US20090042800A1 (en) Assay
US20210346482A1 (en) Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
Zanon et al. Prevalence of antiphospholipid antibodies and lupus anticoagulant in juvenile patients with objectively documented deep-vein thrombosis
US20240052012A1 (en) Platelet alpha-granules for delivery of multiple proteins
CA3022351C (en) Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2025072709A2 (en) Pharmacological suppression of otud4 and cd73 binding, methods of treating cancer, anticancer agents, and therapeutic compositions
CH694905A5 (it) Peptidi derivati dalla proteina HMGB1 per l'immunoterapia attiva nell'infiammazione sistematica letale.
Maat Natural pathways for factor XII activation: Implications for hereditary angioedema
US20160216262A1 (en) Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
Libby Pathobiology of Blood Vessels
Gerdes Atherosclerosis; aspects of a multicultural disease